Chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CSGALNACT1)

Chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CSGALNACT1) is a glycosyltransferase enzyme that catalyzes the transfer of N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the non-reducing end of glucuronic acid on the tetrasaccharide linker of core proteins, a critical step in the initiation and elongation of chondroitin sulfate (CS) chains within proteoglycans[1][2][3]. This enzyme is essential for normal cartilage development and the formation of the extracellular matrix by facilitating proteoglycan biosynthesis, especially in developing skeletal tissues. Loss-of-function mutations lead to reduced chondroitin sulfate production, abnormal cartilage development, and disorders such as mild skeletal dysplasia, advanced bone age, and joint laxity. CSGALNACT1 is also implicated in metabolic pathways related to glycosaminoglycan biosynthesis, and its dysfunction can affect aggrecan metabolism and extracellular matrix integrity[2][3][4]. There is currently no evidence of any approved drugs directly targeting this enzyme, nor established mechanisms of action or safety data for CSGALNACT1-targeted therapies[2][3][4].

Other names

ChGnGALNACT1Beta4GalNAcT-1CSGalNAcT-1ChGn-1CHGNSDJLABAFLJ11264UNQ656/PRO1287chondroitin beta-1,4-N-acetylgalactosaminyltransferase 1glucuronylgalactosylproteoglycan 4-beta-N-acetylgalactosaminyltransferase